Showing papers in "Lung Cancer in 2017"

TL;DR: Elevated pre-treatment NLR and PLR are associated with shorter OS and PFS and with lower response rates in patients with metastatic NSCLC treated with nivolumab independently of other prognostic factors.

TL;DR: In a cohort of patients with NSCLC treated with nivolumab in routine practice, pretreatment NLR≥5 was associated with inferior outcomes, and it is unclear whether this marker is predictive or prognostic.

TL;DR: In NSCLC patients, the confirmed ORR to single-agent chemotherapy after immunotherapy exposure was higher as compared to historical data from the pre-anti-PD1 era, and approached OrR to first-line platinum-based chemotherapy.

TL;DR: Overall, study evidence did not support an association between PD-L1 expression and gender, age, smoking history, tumor histology, performance status, pathologic tumor grade or EGFR/KRAS/ALK mutational status.

TL;DR: Patients with dual TP53/EGFR mutations, especially missense mutations, had marginally lower response rates and shorter PFS when treated with EGFR TKI therapy, and larger datasets are required to validate these observations.

TL;DR: Conurrent mutations, specifically TP53, are common in EGFR mutated lung cancer and may altered clinical outcomes and may alter clinical outcomes.

TL;DR: High plasma sPD-L1 levels were associated with poor prognosis in patients with advanced lung cancer, possibly associated with suppression of anti-tumor immunity.

TL;DR: Favorable responses were observed in patients with G719X and compound L858R mutations, indicating that they may benefit from EGFR-TKIs as a first-line therapy, suggests this retrospective study reviews the prevalence of uncommon EGFR mutations in a Chinese NSCLC cohort.

TL;DR: The current clinical and preclinical data available for small molecule tyrosine kinase inhibitors for non-small cell lung cancers, along with a number of other potential therapeutic options, including antibodies and immunotherapy are reviewed.

TL;DR: Using ctNA analysis as a liquid biopsy in lung cancer has many advantages and allows for a variety of clinical and investigational applications.

TL;DR: A scoping review provides an update on timeliness of lung cancer care over the past decade and suggests that many patients across different facilities and countries appear to be facing substantial waits to receive lung cancer diagnosis and care.

TL;DR: Novel EGFR solvent front mutations at Gly796 (G796S/R) in addition to a hinge pocket L792F/H mutations, and C797S/G all in cis with T790M in a single patient on progression on osimertinib as detected by plasma circulating tumor DNA (ctDNA) assay in the course of clinical care.

TL;DR: A combination of MTAP or BAP1 loss detected by IHC can likely detect MPM with good sensitivity and 100% specificity, and serve as useful ancillary IHC for discriminating MPM from RMH.

TL;DR: Improved detection techniques have broadened the spectrum of reported aberrations within the 'uncommon group' but response to TKIs is variable and not fully elucidated.

TL;DR: Patients who had been diagnosed with neuroendocrine tumors of the lung and had been treated at the National Cancer Center Hospital (Tokyo, Japan) between 1982 and 2010 were assessed for PD-L1 expression.

TL;DR: Circulating free tumour-derived DNA is feasible for mutation analysis employing well-validated and sensitive methods, when tumour samples are unavailable, and testing here may be appropriate, particularly in those with no/remote smoking history.

TL;DR: The effectiveness of nivolumab is reasonable yet less prominent than it has been demonstrated in clinical trials, and ECOG PS ≥2 is associated with poor prognosis.

TL;DR: The usefulness of MYC expression as a surrogate marker of treatment response assessment is worth evaluating for immune checkpoint inhibitor therapy and special interest are required for the subgroup of NSCLC patients, whose tumor expresses PD-L1 and MYC double positive.

TL;DR: The impact of PROMs on the management of lung cancer is reviewed and PROMS have the potential to improve the quality of care with a proper implementation in the routine practice.

TL;DR: In a cohort enriched for advanced NSCLC patients who received platinum-based chemotherapy, STK11 mutations were not specifically associated with clinico-pathological features and they did not impact upon survival and the positive correlation between STK 11 and KRAS mutations is confirmed.

TL;DR: Although the risk factors for nivolumab-induced ILD were not identified, careful monitoring including imaging examinations is important in preventing the worsening of ILD in patients receiving nivollumab.

TL;DR: Surgical resection is associated with significantly longer survival for early SCLC, and new randomized trials should assess trimodality therapy in stages I/II, and in node negative disease.

TL;DR: Afatinib may be a first-choice EGFR-TKI for patients with advanced-stage lung adenocarcinomas harboring non-classical mutations, and set analysis showed that PFS curves of afatinib were more easily distinguished in non- classical EGFR mutations lacking a combination with a classical mutation.

TL;DR: The study demonstrated that the prognostic association of B7-H3 expression indeed differed according to smoking history, and showed the potential effectiveness of anti-B7- H3 therapy for EGFR wild-type or smokers' lung adenocarcinoma.

TL;DR: It is suggested that SBRT utilization for stage I SCLC has increased between 2004 and 2013, highlighting the need for additional research to validate the feasibility of this management approach for inoperable patients.

TL;DR: Higher MHC Class II expression on TILs was correlated with better prognosis in patients with NSCLC and loss of expression of MHC class II on SCLC tumor cells and reduced expression on SclC Tils may be a means of escaping anti-cancer immunity.

TL;DR: The importance of both tissue and blood based hybrid-capture based genomic profiling at disease progression to identifying novel resistance mechanisms in the clinic is demonstrated.

TL;DR: Lack of knowledge about LDCT was a key a barrier across both the PCP and HR, and understanding the barriers to lung screening across diverse community populations is necessary to improve screening rates and shared decision-making.

TL;DR: Preoperative serum albumin level was an important prognostic factor for overall survival and recurrence-free survival in patients with resected non-small cell lung cancer.

TL;DR: The expression of PD-L1 protein was associated with a poor prognosis in lung SCC patients and the 1% cut-off value might become a better predictive marker than the other cut-offs values.